Matthew G. Fury

9.1k total citations
165 papers, 4.4k citations indexed

About

Matthew G. Fury is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Matthew G. Fury has authored 165 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Oncology, 55 papers in Pulmonary and Respiratory Medicine and 41 papers in Otorhinolaryngology. Recurrent topics in Matthew G. Fury's work include Head and Neck Cancer Studies (41 papers), Cancer Immunotherapy and Biomarkers (39 papers) and Lung Cancer Treatments and Mutations (38 papers). Matthew G. Fury is often cited by papers focused on Head and Neck Cancer Studies (41 papers), Cancer Immunotherapy and Biomarkers (39 papers) and Lung Cancer Treatments and Mutations (38 papers). Matthew G. Fury collaborates with scholars based in United States, Australia and Spain. Matthew G. Fury's co-authors include David G. Pfister, Eric J. Sherman, Nancy Y. Lee, Heiko Schöder, Alan L. Ho, Dennis H. Kraus, Jatin P. Shah, Sofia Haque, Kimberly J. Van Zee and Murray F. Brennan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Matthew G. Fury

154 papers receiving 4.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Matthew G. Fury United States 38 2.1k 1.3k 1.2k 1.0k 881 165 4.4k
Roger Ove United States 11 2.0k 0.9× 1.7k 1.3× 1.7k 1.4× 1.1k 1.1× 978 1.1× 36 4.1k
Christina S. Kong United States 35 1.6k 0.7× 737 0.6× 861 0.7× 1.1k 1.1× 1.3k 1.5× 124 4.3k
Ruta Gupta Australia 36 1.6k 0.8× 1.2k 0.9× 803 0.7× 1.4k 1.3× 983 1.1× 197 4.0k
Gerhard G. Grabenbauer Germany 42 3.1k 1.5× 2.0k 1.6× 1.2k 1.0× 2.7k 2.6× 1.0k 1.2× 179 6.8k
Seungwon Kim United States 36 1.8k 0.9× 831 0.6× 1.6k 1.3× 1.5k 1.5× 846 1.0× 119 4.0k
Paul M. Clément Belgium 33 1.5k 0.7× 1.3k 1.0× 584 0.5× 416 0.4× 1.4k 1.5× 136 4.1k
E. Brian Butler United States 35 1.2k 0.6× 2.1k 1.6× 433 0.4× 973 0.9× 792 0.9× 227 4.7k
Remco de Bree Netherlands 34 1.3k 0.6× 885 0.7× 1.4k 1.2× 1.2k 1.2× 457 0.5× 135 3.5k
Ashwatha Narayana United States 29 808 0.4× 1.3k 1.0× 787 0.6× 592 0.6× 485 0.6× 64 3.0k
Yungan Tao France 27 1.0k 0.5× 660 0.5× 1.1k 0.9× 756 0.7× 586 0.7× 112 2.3k

Countries citing papers authored by Matthew G. Fury

Since Specialization
Citations

This map shows the geographic impact of Matthew G. Fury's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew G. Fury with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew G. Fury more than expected).

Fields of papers citing papers by Matthew G. Fury

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew G. Fury. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew G. Fury. The network helps show where Matthew G. Fury may publish in the future.

Co-authorship network of co-authors of Matthew G. Fury

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew G. Fury. A scholar is included among the top collaborators of Matthew G. Fury based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew G. Fury. Matthew G. Fury is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Stratigos, Alexander J., Chieh-I Chen, Cristina Ivanescu, et al.. (2024). Quality of life in cemiplimab-treated patients with locally advanced basal cell carcinoma in a Phase II clinical trial. Future Oncology. 20(30). 2249–2258.
3.
Peris, Ketty, Alexander Stratigos, Karl D. Lewis, et al.. (2024). Health‐related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trial. Cancer Medicine. 13(14). e7360–e7360. 2 indexed citations
4.
Gabrail, Nashat, Miranda Gogishvili, Tamta Makharadze, et al.. (2024). A phase 2/3 study of fianlimab, cemiplimab, plus chemotherapy versus cemiplimab plus chemotherapy in first-line treatment of advanced non-small cell lung cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS8660–TPS8660. 2 indexed citations
5.
Lakhani, Nehal J., Omid Hamid, Irene Braña, et al.. (2024). A phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results.. Journal of Clinical Oncology. 42(16_suppl). 2650–2650. 2 indexed citations
6.
Rischin, Danny, David Miller, Nikhil I. Khushalani, et al.. (2024). 1091P Neoadjuvant cemiplimab for stage II–IV cutaneous squamous cell carcinoma (CSCC): 2-year follow-up and biomarker analyses. Annals of Oncology. 35. S722–S722. 2 indexed citations
7.
Segal, Neil H., Eugenia Girda, Lawrence Fong, et al.. (2023). A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: Trial-in-progress update.. Journal of Clinical Oncology. 41(4_suppl). TPS277–TPS277. 5 indexed citations
8.
Panella, Timothy J., Sajeve Thomas, Meredith McKean, et al.. (2023). A phase 3 trial comparing fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) to pembrolizumab in patients with completely resected high-risk melanoma.. Journal of Clinical Oncology. 41(16_suppl). TPS9598–TPS9598. 1 indexed citations
9.
10.
11.
Migden, Michael R., Danny Rischin, Stacie Hudgens, et al.. (2020). 1087P Time to clinically meaningful changes in pain in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab in a phase II clinical trial. Annals of Oncology. 31. S738–S738. 1 indexed citations
12.
Migden, Michael R., Danny Rischin, Medha Sasané, et al.. (2020). Health-Related Quality of Life (HRQL) in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC) Treated with Cemiplimab: Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial. SKIN The Journal of Cutaneous Medicine. 4(6). s122–s122. 2 indexed citations
13.
Papadopoulos, Kyriakos P., Melissa L. Johnson, A. Craig Lockhart, et al.. (2019). First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies. Clinical Cancer Research. 26(5). 1025–1033. 50 indexed citations
14.
Papadopoulos, Kyriakos P., Rebecca Romero, G. González, et al.. (2017). Anti-Hu-Associated Autoimmune Limbic Encephalitis in a Patient with PD-1 Inhibitor-Responsive Myxoid Chondrosarcoma. The Oncologist. 23(1). 118–120. 50 indexed citations
15.
Falchook, Gerald S., Rom S. Leidner, Elizabeth Stankevich, et al.. (2016). Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. Journal for ImmunoTherapy of Cancer. 4(1). 70–70. 109 indexed citations
16.
Fury, Matthew G., Eric J. Sherman, Alan L. Ho, et al.. (2013). A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer. Cancer. 119(10). 1823–1831. 35 indexed citations
17.
Fury, Matthew G., Nancy Y. Lee, Eric J. Sherman, et al.. (2013). A Phase 1 Study of Everolimus + Weekly Cisplatin + Intensity Modulated Radiation Therapy in Head-and-Neck Cancer. International Journal of Radiation Oncology*Biology*Physics. 87(3). 479–486. 45 indexed citations
18.
Fury, Matthew G., Marija Drobnjak, Camelia S. Sima, et al.. (2010). Tissue microarray evidence of association between p16 and phosphorylated eIF4E in tonsillar squamous cell carcinoma. Head & Neck. 33(9). 1340–1345. 13 indexed citations
19.
Setton, Jeremy, N. Caria, Jonathan Romanyshyn, et al.. (2010). Intensity-Modulated Radiotherapy in the Treatment of Oropharyngeal Cancer: An Update of the Memorial Sloan-Kettering Cancer Center Experience. International Journal of Radiation Oncology*Biology*Physics. 82(1). 291–298. 136 indexed citations
20.
Fury, Matthew G., Cristina R. Antonescu, Kimberly J. Van Zee, Murray F. Brennan, & Robert G. Maki. (2005). A 14-Year Retrospective Review of Angiosarcoma. The Cancer Journal. 11(3). 241–247. 314 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roger Ove Breakdown of academic impact, for papers by Christina S. Kong Breakdown of academic impact, for papers by Ruta Gupta Breakdown of academic impact, for papers by Gerhard G. Grabenbauer Breakdown of academic impact, for papers by Seungwon Kim Breakdown of academic impact, for papers by Paul M. Clément Breakdown of academic impact, for papers by E. Brian Butler Breakdown of academic impact, for papers by Remco de Bree Breakdown of academic impact, for papers by Ashwatha Narayana Breakdown of academic impact, for papers by Yungan Tao
Rankless by CCL
2026